






# Excellent Performance of INDICAID™ Antigen Rapid Diagnostic Test on COVID-19 Clinical Samples with Moderate-high Viral-Loads during the Omicron Epidemiological Wave in Cameroon

FOKAM J<sup>1,2,3</sup>, **TAKOU D<sup>1</sup>**, NGOUFACK E<sup>1,5,6</sup>, DJUPSA S<sup>1</sup>, Grace BELOUMOU<sup>1</sup>, Collins CHENWI<sup>1,7</sup>, Alex Durand NKA<sup>1,4,5</sup>, Davy Hyacinthe ANGUECHIA GOUISSI<sup>1,6</sup>, Aude Christelle KA'E<sup>1,5</sup>, Aurelie KENGNI<sup>1</sup>, Naomi-Karell ETAME<sup>1</sup>, Larissa MOKO<sup>1,6</sup>, Evariste MOLIMBOU<sup>1</sup>, Willy PABO<sup>1</sup>, Rachel Audrey NAYANG MUNDO<sup>1</sup>, Michel TOMMO<sup>1</sup>, Nnomo Zam K<sup>1</sup>, Nadine FAINGUEM<sup>1,4,5</sup>, Aissatou ABBA<sup>1</sup>, Lionele MBA FOTSING<sup>1</sup>, Leaticia Yatchou<sup>1</sup>, OTSHUDIEMA OTOKOYIE J<sup>7</sup>, DJUBGANG DJOUKWE RE<sup>8</sup>, OKOMO ASSOUMOU MC<sup>9,10</sup>, Yap BOUM III<sup>3,10,11</sup>, MBALLA ETOUNDI GA<sup>3,12</sup>, Alexis NDJOLO<sup>1,10</sup>

1.Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon; 2.Faculty of health sciences, University of Buea, Buea, Cameroon; 3.National Public Health Emergency Operations Centre, Ministry of Public Health, Yaounde, Cameroon; 4.Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon; 5.University of Rome "Tor Vergata", Rome, Italy; 6.Faculty of Science and Technology, Evangelic University of Cameroon, Bandjoun, Cameroon; 7.World Health Organisation, Afro, Country office, Yaounde, Cameroon; 8.Directorates for Pharmacy, Drug and Laboratory, Ministry of Public Health, Yaounde, Cameroon; 9.National Public Health Laboratory, Yaounde, Cameroon; 10.Faculty of Medicine and Biomedical sciences, University of Yaounde I, Yaounde, Cameroon; 11.Epicentre, Medecins Sans Frontieres, Yaounde, Cameroon; 12.Department of Disease, Epidemic and Pandemic Control, Ministry of Public Health, Yaounde, Cameroon.



## BACKGROUND

The World Health Organisation recommends the use of COVID-19 antigen rapid diagnostic tests (AgRDT) with at least **80% sensitivity and 97% specificity**. In the era of Omicron variants harbouring several mutations in the viral genes, we sought to ascertain the performance of **INDICAID™ COVID-19 AgRDT** with reference to PCR.

## OBJECTIVES

- 1) Evaluate the sensitivity and the specificity of INDICAID™ AgRDT
- 2) Evaluate the positive (PPV) and the negative predictive values (NPV) of INDICAID™ AgRDT
- 3) Evaluate the turn-around-time of INDICAID™ AgRDT
- 4) Evaluate the genetic diversity and its effect on INDICAID™ AgRDT performance.

## METHODS

An observational laboratory-based study was conducted from March to August 2022 among consenting individuals tested for SARS-COV2 infection at the Virology laboratory of the Chantal BIYA International Reference Centre, Yaoundé-Cameroon. Nasopharyngeal samples were processed both on **INDICAID™ COVID-19 AgRDT** and on DaAn Gene real-time PCR as per national guidelines. Sensitivity, specificity, positive and negative predictive values of **INDICAID™ COVID-19 RDT** were evaluated according to viral load.

## RESULTS & DISCUSSIONS

A total of 565 nasopharyngeal samples were tested from individuals aged  $\geq 21$  years (53.98% males), all residing in Yaoundé and its surroundings, Overall positivity rate was **5.66%(32) with RT-PCR** versus **1.24%(7) with INDICAID™ COVID-19 AgRDT**.

**Table1:**  
Comparison of PCR vs. RDT considering a PCR positivity threshold of 37 (national positivity threshold)

		PCR Positivity at CT<37		
		Positive	Negative	
INDICAID	POSITIVE	07	00	07
	NEGATIVE	25	533	558
		32	533	Total: 565

At **PCR CT<37**, (mean CT =  $33.1 \pm 3.86$ ), sensitivity of INDICAID™ AgRDT was 21.9% (95%CI: [12.5 – 21.9]); specificity was 100% (95%CI: [99.4 – 100]); kappa = 0.346 (95%CI: [0.189 – 0.346]), **suggesting a poor concordance between PCR and rapid test**. PPV was 100% (95%CI: [57.3 – 100]) and NPV was 95.5% (95%CI: [95 – 95.5]).

**Table2:**  
Comparison of PCR vs. RDT considering a PCR positivity threshold of 25 (moderate to high viral loads)

		PCR positivity at CT<25		
		Positive	Negative	
INDICAID	POSITIVE	05	02	07
	NEGATIVE	00	558	558
		05	560	Total: 565

At **PCR CT<25**, (mean CT =  $21.2 \pm 2.34$ ), sensitivity was 100% (95%CI: [51.3 – 100.0]); specificity was 99.6% (95% CI: [99.2 – 99.6]); kappa = 0.832 ([95%CI: 0.422-0.832]), suggesting an **excellent concordance between PCR and rapid test**.

PPV was 71.4% (95% CI: [36.7 – 71.4]) and NPV was 97.7% (95% CI: [97.1 – 97.7]).

Importantly, COVID-19 sequences generated were **100% OMICRON**, sub-variant BA.1.

## Conclusions

For patients infected with **moderate-high viral loads**, INDICAID™ AgRDT has **high intrinsic (sensitivity and specificity) and extrinsic (predictive values) performances for the diagnosis of COVID-19**. With its simplicity and short turn-around-time ( $15 \pm 2$ min), INDICAID™ COVID-19 AgRDT is a reliable tool to prevent the spread of COVI-19 at community-level, even on circulating Omicron variants.

## Recommendations

- **Wide use of INDICAID™ COVID-19 AgRDT for rapid diagnosis of asymptomatic cases with moderate to high viral loads.**

## Acknowledgements

All the study participants  
CIRCB staff & management  
EDCTP (RIA2020-EF3000)

